Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic plasma levels and induce effective diuresis. The test formulation in this study is a buffered solution, Furosemide Injection Solution at 30 mg/mL at pH 7.4 (range 7.0 to 7.8) and is intended for SC injection according to the instructions in the protocol. A commercial formulation of Furosemide Injection, USP will serve as the reference drug in this study, which will be administered by IV bolus. It contains furosemide 10 mg/mL in solution at alkaline pH of 8.0 to 9.3 and is marketed for IV and IM injection. The primary objective of the study is to estimate the absolute bioavailability of furosemide administered by subcutaneous infusion compared with an equivalent dose of furosemide administered by IV bolus administration.
Description: Maximum plasma furosemide concentration after administration by subcutaneous infusion or IV bolus
Measure: Pharmacokinetic - Cmax Time: 0 to 24 hoursDescription: Area under the concentration versus time curve (AUC) from time 0 to the last measurable plasma furosemide concentration after administration by subcutaneous infusion or IV bolus
Measure: Pharmacokinetic - AUClast Time: 0 to 24 hoursDescription: AUC from time 0 to infinity for plasma furosemide after administration by subcutaneous infusion or IV bolus
Measure: Pharmacokinetic - AUCinf Time: 0 to 24 hoursDescription: Total collected urine volume after furosemide administration by subcutaneous infusion or IV bolus
Measure: Pharmacodynamic - Diuresis Time: 0 to 8 hoursDescription: Total collected urine volume after furosemide administration by subcutaneous infusion or IV bolus
Measure: Pharmacodynamic - Diuresis Time: 0 to 24 hoursDescription: Total sodium concentration in urine after furosemide administration by subcutaneous infusion or IV bolus
Measure: Pharmacodynamic - Natriuresis Time: 0 to 8 hoursDescription: Total sodium concentration in urine after furosemide administration by subcutaneous infusion or IV bolus
Measure: Pharmacodynamic - Natriuresis Time: 0 to 24 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports